Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer
Company stage: Solid tumours
Diseases (gene editing): Cancer
Genome editing tool: TALEN
Funding stage: Public (NASDAQ:IOVA)
Location: San Carlos, CA, USA
Gene-editing partnerships: Cellectis
Iovance Biotherapeutics is a clinical stage company focusing on the development of cellular therapies. The company develops tumour infiltrating lymphocyte (TIL)-based therapies to treat various types of solid tumours. The company's engagemen in the gene-editing space comes through its collaboration with Cellectis, from which it has licenced the TALEN technology to develop PD-1 inactivated TILs.